Carmat is a France-based company dedicated to designing, manufacturing, and marketing Aeson, the artificial heart. The company's mission is to establish Aeson as the primary alternative to heart transplantation, offering a life-saving therapeutic option for patients with end-stage biventricular heart failure who face a severe shortage of donor hearts.
2008
153
Last FY Revenue $8.1M
Last FY EBITDA -$57.5M
$69.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Carmat reported revenue of $8.1M and EBITDA of -$57.5M.
Carmat expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Carmat valuation multiples based on analyst estimates| NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|
| Revenue | XXX | $8.1M | XXX | XXX | XXX |
| Gross Profit | XXX | -$27.3M | XXX | XXX | XXX |
| Gross Margin | XXX | -337% | XXX | XXX | XXX |
| EBITDA | XXX | -$57.5M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -707% | XXX | XXX | XXX |
| EBIT | XXX | -$46.5M | XXX | XXX | XXX |
| EBIT Margin | XXX | -573% | XXX | XXX | XXX |
| Net Profit | XXX | -$59.6M | XXX | XXX | XXX |
| Net Margin | XXX | -734% | XXX | XXX | XXX |
| Net Debt | XXX | $61.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Carmat has current market cap of EUR 6.4M (or $7.4M), and EV of EUR 59.5M (or $69.0M).
As of January 19, 2026, Carmat's stock price is EUR 0 (or $0).
See Carmat trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $69.0M | $7.4M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialCarmat's trades at 8.5x EV/Revenue multiple, and -1.2x EV/EBITDA.
See valuation multiples for Carmat and 15K+ public compsAs of January 19, 2026, Carmat has market cap of $7.4M and EV of $69.0M.
Equity research analysts estimate Carmat's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Carmat's P/E ratio is not available.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7.4M | XXX | $7.4M | XXX | XXX | XXX |
| EV (current) | $69.0M | XXX | $69.0M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 8.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -1.2x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -1.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -0.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCarmat's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Carmat's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Carmat's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Carmat and other 15K+ public comps| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 236% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Carmat acquired XXX companies to date.
Last acquisition by Carmat was XXXXXXXX, XXXXX XXXXX XXXXXX . Carmat acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Carmat founded? | Carmat was founded in 2008. |
| Where is Carmat headquartered? | Carmat is headquartered in France. |
| How many employees does Carmat have? | As of today, Carmat has 153 employees. |
| Is Carmat publicy listed? | Yes, Carmat is a public company listed on PAR. |
| What is the stock symbol of Carmat? | Carmat trades under ALCAR ticker. |
| When did Carmat go public? | Carmat went public in 2010. |
| Who are competitors of Carmat? | Similar companies to Carmat include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Carmat? | Carmat's current market cap is $7.4M |
| Is Carmat profitable? | Yes, Carmat is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.